Two papers by Wang Xuehao , an academician of the Chinese Academy of Engineering and director of the Hepatobiliary Center of Jiangsu Provincial People's Hospital (the First Affiliated Hospital of Nanjing Medical University) as co-corresponding authors have been successively published due to suspected reuse of images, contamination of cell lines, and lack of patient consent statements. withdraw.
The above paper was withdrawn on February 9, 2023 due to suspected image reuse and other issues.
On February 9, 2023, the international academic journal "Cell Death & Disease" (Cell Death & Disease) published online a retraction statement stating that the title was "Reducing Hippo Signaling by Targeting PTPRB, miR-665 Promotes Migration of Hepatocellular Carcinoma Cells" , Invasion and Proliferation" (miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB) was published online on September 20, 2018, due to cell images and tissue images in some pictures overlap, as well as the cell lines used in their experiments, raised concerns among readers. Currently, the paper has been retracted.
Wang Xuehao, academician of the Chinese Academy of Engineering, and Rao Jianhua, deputy chief physician and associate professor of the Hepatobiliary Center of Jiangsu Provincial People's Hospital (the First Affiliated Hospital of Nanjing Medical University), are the co-corresponding authors of the paper.
Specifically, there appears to be overlap between images representing different groups in Figure 2A and Figure 2B of the paper in question; the 0-hour images of NC and pre-miR-665 in Figure 2C appear to be from the same Samples; images representing different groups in Figure 5C and Figure 5D appear to overlap; PTPRB images of the pre-miR-665 group in Figure 8E and Figure 8F appear to contain overlapping regions; L02 and SMMC-7721 cell lines are allegedly contaminated with HeLa cells , not suitable for liver cancer research; HepG2 cells are known to be unsuitable as a model of hepatocellular carcinoma. In addition, there is no statement of patient consent in the paper.
The above-mentioned retraction notes mentioned that the signed authors stated that the relevant image errors were caused by incorrect data storage. “The editorial board no longer has confidence in the data it published and in the ethics of the study. Yuanchang Hu agreed to retract the paper on behalf of all authors,” said Yuanchang Hu.
The Paper noticed that in January 2021, on the review website PubPeer after the paper was published, some users successively questioned that there were image duplication problems in many of its pictures. Jianhua Rao replied in January 2021, "Through further investigation, deliberate academic fraud can be ruled out, and the scientific conclusions of the paper have not changed. However, some wrong images were inadvertently used; our graduate students are saving these images. I made a big mistake when I mistakenly saved some pictures from the same group to a different group. We apologize for this mistake. We are contacting the journal for revisions and errata."
But then, a user commented, "There are so many mistakes, your research is no longer credible. Please retract the paper."
The above paper was retracted on December 1, 2021 at the author's request due to image reproduction issues.
In addition to the retraction of the above-mentioned papers, on December 1, 2021, the international academic journal "Hepatology" published a retraction statement stating that the title is "M2 macrophage-derived exosomes transfer αMβ2 integrin After M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by TransferringαMβ2 Integrin to Tumor Cells was published online on June 28, 2020, some readers questioned the contents of pictures 2F, 3H, 6A and 6B There is an image duplication issue. After investigation, the authors confirmed that a replication error had occurred and requested that the paper be retracted. Currently, the paper has been retracted.
Wang Xuehao , academician of the Chinese Academy of Engineering, Tang Jinhai, chief physician of Jiangsu Provincial People's Hospital (First Affiliated Hospital of Nanjing Medical University), Zhang Yaqin, associate researcher of the Department of Biochemistry and Molecular Biology, School of Basic Medicine, Nanjing Medical University, and Jiangsu Provincial People's Hospital (First Affiliated Hospital of Nanjing Medical University) Wu Jindao, deputy chief physician and professor of the Hepatobiliary Center of the Affiliated Hospital, is the co -corresponding author of the paper.
The Paper noticed that before the above-mentioned paper was withdrawn, in October 2021, readers successively questioned the overlap problem of multiple pictures of the paper on the review website PubPeer after the paper was published.
According to the official website information of Jiangsu Provincial People's Hospital (the First Affiliated Hospital of Nanjing Medical University), Wang Xuehao is the academic leader of the Hepatobiliary Center of the hospital, an academician of the Chinese Academy of Engineering, a first-class professor, chief physician, and doctoral supervisor; he is a well-known expert in organ transplantation and hepatobiliary surgery in China. , is the pioneer of living donor liver transplantation and interventional therapy for liver cancer in China . His main research fields are the basic and clinical aspects of liver transplantation, especially post-transplantation immune tolerance; he is the director of the Institute of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, the director of the Hepatobiliary Center, and the director of the National Health Commission’s key clinical department of organ transplantation. Director of Clinical Key Laboratory of National Health Commission.
Tang Jinhai is a doctor of surgery, professor, chief physician, and doctoral supervisor. His main research directions are breast cancer diagnosis, surgical treatment, screening and mechanism research of molecular markers related to breast cancer prognosis. Tang Jinhai used to be Secretary of the Party Committee of Jiangsu Provincial People's Hospital, the First Affiliated Hospital of Nanjing Medical University, and Vice President of Nanjing Medical University. Subjects, outstanding talents of the "Science, Education and Health" project in Jiangsu Province, enjoy the special government allowance of the State Council.
Zhang Yaqin is an associate researcher at the Department of Biochemistry and Molecular Biology, School of Basic Medicine, Nanjing Medical University, Ph.D., and master supervisor. Her main research interests include metabolic imbalance in type 2 diabetes and islet cell function, and immunological mechanisms of metabolic diseases.
Wu Jindao is the deputy chief physician and professor of the Hepatobiliary Center of Jiangsu Provincial People's Hospital (the First Affiliated Hospital of Nanjing Medical University). Its main directions are liver benign and malignant tumors (primary liver cancer, metastatic liver cancer, hepatic hemangioma, etc.), gallbladder cancer, biliary tract tumors, hepatic bile duct stones, cholecystitis and cholelithiasis, liver cysts, portal hypertension, splenomegaly, hypersplenism etc.
